Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Epstein-linked longevity guru Peter Attia leaves David Protein, and his own startup ‘won’t comment’

From TechCrunch

By Julie Bort

February 4, 2026

Epstein-linked longevity guru Peter Attia leaves David Protein, and his own startup ‘won’t comment’

Epstein-linked longevity guru Peter Attia leaves David Protein, and his own startup ‘won’t comment’

The founder of David Protein, maker of popular high-protein nutrition bars, announced on X on Monday that longevity guru Dr. Peter Attia “has stepped down from his role as Chief Science Officer at David.”

The announcement comes after Attia’s name appeared in more than 1,700 documents, including email correspondence, released on Friday as part of a massive file dump related to convicted sex offender Jeffrey Epstein, according to The New York Times. Attia served on the executive team of the food startup and was also an early investor.

For those unfamiliar, Attia is a Canadian American physician who has become one of the most prominent voices in longevity and preventive health. He’s best known for his bestselling book “Outlive: The Science and Art of Longevity” and his now seven-year-old podcast, wherein he explores optimization strategies. He was also hired just last month as a contributor to CBS.

Three-year-old, New York-based David Protein raised a $75 million Series A funding round in May of last year led by Greenoaks, with participation from Valor Equity Partners. The company has experienced significant growth since launching its flagship protein bar in September 2024, a product it describes as having 28 grams of protein, zero sugar, and 150 calories.

In a lengthy post on X, Attia wrote that he was “ashamed” of some of the crude content in his emails with Epstein, but he also said he was not involved in criminal activity and never visited Epstein’s island or traveled on his plane. Attia also discussed at length how he came to know Epstein and why he stayed involved with him even after Epstein’s 2008 conviction.

The fallout appears to extend beyond David Protein. It also appears that Biograph, the healthcare testing and longevity startup that Attia co-founded with entrepreneur John Hering, may be distancing itself from the physician. The company declined to comment on Attia’s ongoing participation with the startup or about the pages on its website that used to mention him but now omit his name or return a “file not found” error.

Biograph came out of stealth a year ago, TechCrunch previously reported, with backing from investors that include Vy Capital, Human Capital, Alpha Wave, and WndrCo, along with angel investors, including Balaji Srinivasan. Like a growing number of concierge medical service companies, Biograph offers premium preventive health services to subscribers who pay between $7,500 and $15,000 per year. Attia was previously named on the company’s press release and site as a co-founder.

View original article on techcrunch.com

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

What the Epstein files reveal about EV startups and Silicon Valley

What the Epstein files reveal about EV startups and Silicon Valley

Will the Epstein revelations lead to broader fallout in Silicon Valley?

Feb 15, 2026

VC Masha Bucher, Epstein associate and Day One founder, explains herself

VC Masha Bucher, Epstein associate and Day One founder, explains herself

After numerous news reports documented Masha Bucher's close business and personal relationship with convicted sex offender Jeffrey Epstein, Bucher took to X to explain.

Feb 10, 2026

AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.

AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.

10x Science has raised a $4.8 million seed round to help pharmaceutical researchers understand complex molecules.

Apr 22, 2026

Tony Robbins and Peter Diamandis’ longevity company Fountain Life raises $18M

Tony Robbins and Peter Diamandis’ longevity company Fountain Life raises $18M

The first principal of longevity is, “Don't die of anything stupid,” CEO Dr. William Kapp says. New funding will support mulit-state expansion.

Aug 13, 2025

Most Recent

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow emerges from stealth at $1.2B valuation to challenge endpoint security in the AI era

Glow is targeting a new class of endpoint risks created by the rapid adoption of AI agents and developer tools inside enterprises.

Jul 22, 2026

Similar Posts

What the Epstein files reveal about EV startups and Silicon Valley

What the Epstein files reveal about EV startups and Silicon Valley

Will the Epstein revelations lead to broader fallout in Silicon Valley?

Feb 15, 2026

VC Masha Bucher, Epstein associate and Day One founder, explains herself

VC Masha Bucher, Epstein associate and Day One founder, explains herself

After numerous news reports documented Masha Bucher's close business and personal relationship with convicted sex offender Jeffrey Epstein, Bucher took to X to explain.

Feb 10, 2026

AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.

AI is spitting out more potential drugs than ever. This startup wants to figure out which ones matter.

10x Science has raised a $4.8 million seed round to help pharmaceutical researchers understand complex molecules.

Apr 22, 2026

Tony Robbins and Peter Diamandis’ longevity company Fountain Life raises $18M

Tony Robbins and Peter Diamandis’ longevity company Fountain Life raises $18M

The first principal of longevity is, “Don't die of anything stupid,” CEO Dr. William Kapp says. New funding will support mulit-state expansion.

Aug 13, 2025